Aldeyra Therapeutics. has been granted a patent for small molecule therapeutics that act as scavengers for toxic aldehydes. The invention includes free-base and salt forms, as well as compositions for treating diseases linked to aldehyde toxicity. The patent specifically claims a solid form of Compound 5. GlobalData’s report on Aldeyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aldeyra Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Aldeyra Therapeutics's grant share as of June 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Aldehyde-scavenging small molecule therapeutics for disease treatment
The granted patent US12029735B2 outlines claims related to a solid form of Compound 5, specifically focusing on its crystalline characteristics and purity. The claims detail that the solid form is substantially free of amorphous content and impurities, with specific requirements for its X-ray powder diffraction (XRPD) patterns. Notably, the solid form can exhibit at least two distinct peaks in its XRPD at specified degrees, indicating its crystalline nature. The patent also distinguishes between different forms of the compound, such as Form A and Form B, each with unique XRPD profiles. Additionally, the claims encompass pharmaceutical compositions that include this solid form along with acceptable carriers or excipients.
Furthermore, the patent describes methods for treating various conditions associated with aldehyde toxicity, which may include ocular diseases like dry eye and cataracts, skin disorders such as psoriasis and dermatitis, and other systemic conditions like asthma and Alzheimer's disease. The claims allow for the administration of the solid form or its compositions to patients, potentially in conjunction with other therapeutic agents. The comprehensive nature of the claims highlights the versatility of the solid form of Compound 5 in addressing a wide range of medical conditions, emphasizing its potential therapeutic applications in both ocular and dermatological contexts, as well as broader systemic diseases.
To know more about GlobalData’s detailed insights on Aldeyra Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
